
Atopic Dermatitis
Latest News

Latest Videos

CME Content
More News

Mobile app SkinTracker enhances atopic dermatitis care through remote assessments, proving effective and convenient for patients while saving costs.

Panelists discuss how the current topical standard of care has evolved from traditional topical steroids developed in the 1960s to include newer nonsteroidal options like ruxolitinib (Janus kinase [JAK] inhibitor), roflumilast (phosphodiesterase-4 [PDE4] inhibitor), and tapinarof (aryl hydrocarbon receptor agonist), with steroids now serving as bridge treatments rather than long-term maintenance therapy.

Panelists discuss how atopic dermatitis presents differently across pediatric age groups. Infants show lesions on cheeks and extensor surfaces, whereas older children develop more typical flexural patterns. They also discuss how the condition significantly impacts the quality of life for patients and caregivers through sleep disruption, school performance issues, and ongoing parental stress.

A novel 4% glycyrrhetinic acid scalp gel shows rapid relief for mild to moderate seborrheic dermatitis, enhancing treatment options with herbal ingredients.

During a Case-Based Roundtable event, Naiem Issa, MD, PhD, guided colleagues through 3 complex atopic dermatitis cases, highlighting how modern topicals can deliver rapid and durable control across age groups.

Panelists discuss how OX40-pathway therapies may serve as first-line treatments after topicals due to their promising efficacy and safety profiles, though questions remain about optimal patient selection, long-term safety, and predictive biomarkers.

Panelists discuss how multiple OX40 pathway–targeted drugs are in development, including rocatinlimab (anti-OX40, cell depleting) and amlitelimab (anti-OX40L, nondepleting), both showing promising phase 2/3 results with potential for sustained responses.

Radiation dermatitis significantly affects breast cancer patients, impacting quality of life and treatment. Discover effective prevention and management strategies.

The FDA has approved roflumilast 0.05% cream for atopic dermatitis in children aged 2 years and older, extending its use to a critical pediatric population.

The biologic’s less frequent injections could ease logistical and emotional strain for patients with atopic dermatitis and their families.

Sitryx Therapeutics advances SYX-5219 for moderate to severe AD, aiming for a first-in-class oral treatment with potential for lasting disease remission.

Panelists discuss how OX40 pathway–targeted therapies may benefit specific patient subsets with particular immunologic profiles and could potentially modify the disease course when used early, although patient selection criteria remain unclear.

Panelists discuss how the OX40-OX40L costimulatory pathway represents a promising upstream target for atopic dermatitis treatment by modulating T-cell survival, expansion, and memory formation rather than targeting downstream cytokines. Panelists discuss how targeting the OX40-OX40L pathway could potentially provide broader therapeutic effects across multiple T-cell subsets and offer more durable responses than current cytokine-specific or JAK inhibitor approaches.

The approval represents the sixth FDA authorization for roflumilast since 2022.

Patient advocate Danielle Jonas shares her journey with atopic dermatitis, emphasizing the importance of trusted products and clinician support during Eczema Awareness Month.

Mary W. Chang, MD, discusses the expanded FDA approval of ruxolitinib cream for children with atopic dermatitis and its role in addressing treatment gaps, safety, and real-world use.

Panelists discuss how the OX40-OX40L costimulatory pathway represents a promising upstream target for atopic dermatitis treatment by modulating T-cell survival, expansion, and memory formation rather than targeting downstream cytokines.

Panelists discuss how atopic dermatitis involves complex T-cell–mediated immune dysfunction beyond just Th2 pathways, with antigen-presenting cells driving naive T-cell activation and differentiation into multiple T-cell subsets that produce various inflammatory cytokines.

Bambusa Therapeutics reveals promising phase I trial results for BBT001, targeting atopic dermatitis with dual-action bispecific antibodies.

TRIV-509 is a dual KLK5/7 inhibitor that aims to address barrier dysfunction, inflammation, and itch in moderate to severe AD.

This episode explores the controversy and lack of clear diagnostic criteria for TSW.












